ATNM - Wutah pendapatan YoY sajrone 12 wulan kepungkur actiniumpharma.com

Logo grafis Actinium Corp (ATNM)

Actinium Pharmaceuticals (ATNM) leads the development of advanced radiopharmaceuticals for the therapy of hematological tumors, actively advancing the Iomab-B project. The company's TTM revenue growth rate visualizes this progress, where the 38843.70 mark reflects the current state. A unique isotope delivery method will ensure complete pricing power, although the business currently relies heavily on external contractors for stable drug production.

Actinium Pharmaceuticals Inc - Wutah dodolan YoY (TTM) ATNM (periode 11.02.2024 - 18.11.2026)

Actinium Pharma (ATNM) - rincian metrik lan laporan keuangan

Pambiji fundamental perusahaan:ATNM (Actinium Corp)
Barang unggulan Actinium Pharmaceuticals, Inc.

Investors are evaluating Actinium Pharmaceuticals (ATNM) through the lens of its unique positioning in radiopharmaceuticals. This metric measures the daily change in annual revenue over a rolling 12-month period, revealing the actual vector of operational growth. Analyzing the year-over-year sales growth percentage for TTM allows for tracking revenue acceleration prior to the market launch of Iomab-B. Complex isotope logistics minimize competition, making this indicator a key marker of commercial scaling. A stable trend will confirm the fundamental resilience of the business.